Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
-
Published:2020-12
Issue:6
Volume:73
Page:1460-1469
-
ISSN:0168-8278
-
Container-title:Journal of Hepatology
-
language:en
-
Short-container-title:Journal of Hepatology
Author:
Sangro Bruno,
Melero Ignacio,
Wadhawan Samir,
Finn Richard S.ORCID,
Abou-Alfa Ghassan K.,
Cheng Ann-Lii,
Yau Thomas,
Furuse JunjiORCID,
Park Joong-WonORCID,
Boyd Zachary,
Tang Hao (Tracy),
Shen YunORCID,
Tschaika Marina,
Neely Jaclyn,
El-Khoueiry Anthony
Funder
Bristol-Myers Squibb
Ono Pharmaceutical
Reference33 articles.
1. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017
2. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma;Abou-Alfa;N Engl J Med,2018
3. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial;Zhu;Lancet Oncol,2019
4. Immune checkpoint inhibitors in hepatocellular carcinoma: opportunities and challenges;Liu;Oncologist,2019
5. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial;El-Khoueiry;Lancet,2017
Cited by
283 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献